Trial reportAmyotrophic lateral sclerosis & frontotemporal degeneration2021
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of
Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Amyotrophic lateral sclerosis & frontotemporal degeneration, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Efficacy and safety of pharmacological and biological therapies for amyotrophic lateral sclerosis: a network meta-analysis.Frontiers in neurologyPooled it
- Review
- Sulforaphane-Mediated Multitarget Therapeutic Effects in Methylmercury-Induced ALS-Like Pathology: Comparative Analysis and Multifaceted Approach to Neuroprotection and Systemic Recovery.Molecular neurobiology · 2026Article
- Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS.Journal of neuromuscular diseases · 2025Article
- Analysis of metabolites and metabolic pathways of troponin activator in rats using UHPLC-MS.Analytical and bioanalytical chemistry · 2025Article
- Rethinking phase 2 trials in amyotrophic lateral sclerosis.Brain : a journal of neurology · 2025Article
- Prognostic Factors and Epidemiology of Amyotrophic Lateral Sclerosis in Southeastern United States.Mayo Clinic proceedings. Innovations, quality & outcomes · 2024Article
- Congenital myopathies: pathophysiological mechanisms and promising therapies.Journal of translational medicine · 2024Review
- Skeletal muscle in amyotrophic lateral sclerosis.Brain : a journal of neurology · 2023Review
- Therapeutic targeting of ALS pathways: Refocusing an incomplete picture.Annals of clinical and translational neurology · 2023Review
- Small molecule drugs to improve sarcomere function in those with acquired and inherited myopathies.American journal of physiology. Cell physiology · 2023Review
- Review
- Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder.Biomedicines · 2023Review
- Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation.Nature reviews. Drug discovery · 2023Review
- Public Health Need, Molecular Targets, and Opportunities for the Accelerated Development of Function-Promoting Therapies: Proceedings of a National Institute on Aging Workshop.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Article
- Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022Review
- Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.International journal of molecular sciences · 2022Review
- Gene Transfer of Skeletal Muscle-Type Myosin Light Chain Kinase via Adeno-Associated Virus 6 Improves Muscle Functions in an Amyotrophic Lateral Sclerosis Mouse Model.International journal of molecular sciences · 2022Article
- Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.Muscle & nerve · 2022Article
- Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle.Cells · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
53 authors at 20 institutions in 5 countries.
Jeremy M ShefnerBarrow Neurological Institute, Phoenix, AZ, USA.
Jinsy A AndrewsThe Eleanor and Lou Gehrig ALS Center, The Neurological Institute, New York, NY, USA.
Angela GengeMontreal Neurological Institute, Montreal, QC, Canada.
Carlayne JacksonUniversity of Texas Health Science Center, San Antonio, TX, USA.
Noah LechtzinJohns Hopkins School of Medicine, Baltimore, MD, USA.
Timothy M MillerWashington University School of Medicine, St. Louis, MO, USA.
Bettina M CockroftCytokinetics, Inc, South San Francisco, CA, USA.
Lisa MengCytokinetics, Inc, South San Francisco, CA, USA.
Jenny WeiCytokinetics, Inc, South San Francisco, CA, USA.
Andrew A WolffCytokinetics, Inc, South San Francisco, CA, USA.
Fady I MalikCytokinetics, Inc, South San Francisco, CA, USA.
Cynthia BodkinIndiana University School of Medicine, Indianapolis, IN, USA.
Benjamin R BrooksAtrium Health Neurosciences Institute-Carolinas Neuromuscular/ALS MDA Care Center, Charlotte, NC, USA.
James CaressWake Forest Health Sciences, Winston-Salem, NC, USA.
Annie DionneCHU de Québec, Université Laval, Quebec, Canada.
Dominic FeeMedical College of Wisconsin, Milwaukee, WI, USA.
Stephen A GoutmanUniversity of Michigan, Ann Arbor, MI, USA.
Namita A GoyalThe ALS & Neuromuscular Center, UCI Health, Orange, CA, USA.
Orla HardimanTrinity College, Beaumont Hospital, Dublin, Ireland.
Ghazala HayatSt. Louis University, St. Louis, MO, USA.
Terry Heiman-PattersonLewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
Daragh HeitzmanTexas Neurology, Dallas, TX, USA.
Robert D HendersonRoyal Brisbane and Women's Hospital, Herston, Australia.
Wendy JohnstonUniversity of Alberta, Edmonton, AB, Canada.
Chafic KaramOregon Health & Science University, Portland, OR, USA.
Matthew C KiernanRoyal Prince Alfred Hospital, University of Sydney, Sydney, Australia.
Stephen J KolbWexner Medical Center, Ohio State University, Columbus, OH, USA.
Lawrence KorngutUniversity of Calgary, Calgary, AB, Canada.
Shafeeq LadhaSt. Joseph's Hospital and Medical Center, Neurological Institute, AZ, USA Barrow Phoenix.
Genevieve MatteCentre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Jesus S MoraHospital San Rafael, Madrid, Germany.
Merrilee NeedhamPerron Institute, Department of Neurology, Fiona Stanley Hospital, The University of Notre Dame Australia, Murdoch University, Perth, Australia.
Bjorn OskarssonMayo Clinic Florida, Jacksonville, FL, USA.ORCID 0000-0002-1725-9866
Gary L PatteeNeurology Associates, Lincoln, NE, USA.
Erik P PioroCleveland Clinic, Cleveland, OH, USA.
Michael PulleyUniversity of Florida, Jacksonville, FL, USA.
Dianna QuanUniversity of Colorado Denver, Aurora, CO, USA.
Kourosh RezaniaUniversity of Chicago Medical Center, Chicago, IL, USA.
Kerri L SchellenbergUniversity of Saskatchewan, Saskatoon, SK, Canada.ORCID 0000-0002-5820-2428
David SchultzFlinders Medical Centre, Bedford Park, Australia.
Christen ShoesmithLondon Health Sciences Centre, London, ON, Canada.
Zachary SimmonsPenn State Hershey Medical Center, Hershey, PA, USA.
Jeffrey StatlandUniversity of Kansas Medical Center, Kansas City, KS, USA.
Shumaila SultanWest Virginia University, Morgantown, WV, USA.
Andrea SwensonUniversity of Iowa, Iowa City, IA, USA.
Leonard H Van Den BergDepartment of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.
Tuan VuUniversity of South Florida, Tampa, FL, USA.
Steve VucicWestmead Hospital, Sydney, Australia.
Michael WeissUniversity of Washington, Seattle, WA, USA.
Ashley Whyte-RaysonDuke University School of Medicine, Durham, NC, USA.
James WymerUniversity of Florida, Gainesville, FL, USA.
Lorne ZinmanALS/Neuromuscular Clinic Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Stacy A RudnickiCytokinetics, Inc, South San Francisco, CA, USA.
Cytokinetics (United States) · USUniversity of Florida · USBarrow Neurological Institute · USBeaumont Hospital · IECentre Hospitalier de l’Université de Montréal · CACleveland Clinic · USDuke University · USFlinders Medical Centre · AUIndiana University School of MedicineJacksonville College · USJohns Hopkins University · USLondon Health Sciences Centre · CAMedical College of Wisconsin · USMontreal Neurological Institute and Hospital · CAMurdoch University · AUNeurosciences Institute · USOregon Health & Science University · USPenn State Milton S. Hershey Medical Center · USRoyal Brisbane and Women's Hospital · AUSaint Louis University · US
Funding
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3MNCATS NIH HHS UL1 TR001420
Abstract
objectiveTo evaluate safety, dose response, and preliminary efficacy of
Indexed as
Amyotrophic Lateral SclerosisDouble-Blind MethodHumansMuscle Strengthamyotrophic lateral sclerosisRandomized clinical trialreldesemtiv
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.